Ptc Therapeutics Stock Probability of Future Stock Price Finishing Over 43.88

PTCT Stock  USD 49.99  1.93  4.02%   
PTC Therapeutics' future price is the expected price of PTC Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of PTC Therapeutics performance during a given time horizon utilizing its historical volatility. Check out PTC Therapeutics Backtesting, PTC Therapeutics Valuation, PTC Therapeutics Correlation, PTC Therapeutics Hype Analysis, PTC Therapeutics Volatility, PTC Therapeutics History as well as PTC Therapeutics Performance.
For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide.
  
Price To Sales Ratio is likely to drop to 2.09 in 2024. Price Earnings Ratio is likely to drop to -3.46 in 2024. Please specify PTC Therapeutics' target price for which you would like PTC Therapeutics odds to be computed.

PTC Therapeutics Target Price Odds to finish over 43.88

The tendency of PTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay above $ 43.88  in 90 days
 49.99 90 days 43.88 
about 21.74
Based on a normal probability distribution, the odds of PTC Therapeutics to stay above $ 43.88  in 90 days from now is about 21.74 (This PTC Therapeutics probability density function shows the probability of PTC Stock to fall within a particular range of prices over 90 days) . Probability of PTC Therapeutics price to stay between $ 43.88  and its current price of $49.99 at the end of the 90-day period is about 19.8 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.16 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, PTC Therapeutics will likely underperform. Additionally PTC Therapeutics has an alpha of 0.644, implying that it can generate a 0.64 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   PTC Therapeutics Price Density   
       Price  

Predictive Modules for PTC Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as PTC Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of PTC Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
45.7749.9954.21
Details
Intrinsic
Valuation
LowRealHigh
44.9954.8259.04
Details
Naive
Forecast
LowNextHigh
48.1552.3756.58
Details
16 Analysts
Consensus
LowTargetHigh
32.2335.4239.32
Details

PTC Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. PTC Therapeutics is not an exception. The market had few large corrections towards the PTC Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold PTC Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of PTC Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.64
β
Beta against Dow Jones1.16
σ
Overall volatility
4.75
Ir
Information ratio 0.16

PTC Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of PTC Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for PTC Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
PTC Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 937.82 M. Net Loss for the year was (626.6 M) with profit before overhead, payroll, taxes, and interest of 2.63 M.
PTC Therapeutics currently holds about 288.43 M in cash with (158.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.01.
Over 98.0% of the company shares are owned by institutional investors
Latest headline from benzinga.com: Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder

PTC Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of PTC Stock often depends not only on the future outlook of the current and potential PTC Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. PTC Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding74.8 M
Cash And Short Term Investments876.7 M

PTC Therapeutics Technical Analysis

PTC Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. PTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of PTC Therapeutics. In general, you should focus on analyzing PTC Stock price patterns and their correlations with different microeconomic environments and drivers.

PTC Therapeutics Predictive Forecast Models

PTC Therapeutics' time-series forecasting models is one of many PTC Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary PTC Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about PTC Therapeutics

Checking the ongoing alerts about PTC Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for PTC Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
PTC Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 937.82 M. Net Loss for the year was (626.6 M) with profit before overhead, payroll, taxes, and interest of 2.63 M.
PTC Therapeutics currently holds about 288.43 M in cash with (158.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.01.
Over 98.0% of the company shares are owned by institutional investors
Latest headline from benzinga.com: Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder

Additional Tools for PTC Stock Analysis

When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.